BLCO

Bausch & Lomb Corp

NYSE · Ophthalmic Goods · CIK 0001860742
$15.42 -1.46% $5.6B
Insider Buying Cluster (9 insiders)High Impact Filing (7/10)
Vol
Market Cap$5.6B
Cap SizeMid Cap
Analyst ConsensusBuy (50%)
Inst. Holders4 funds
Inst. Value$37.9M
Inst. Activity2 buys / 0 sells
Insider Activity7B / 0S
Insider Net $$1.1M
SEC Reports7
Exchange NYSE·Sector Ophthalmic Goods·CIK 0001860742·Prev Close $15.65

Recent Activity

May 28, 2026 Event
Siliq
WARNING: SUICIDAL IDEATION AND BEHAVIOR Suicidal ideation and behavior, including completed suicides
May 26, 2026 Insider
Alfonso Eduardo sold 15,842 shares
Director @ $15.78 ($250.0K)
May 26, 2026 Insider
Bernier Nathalie D. sold 15,842 shares
Director @ $15.78 ($250.0K)
May 26, 2026 Insider
COLLIS STEVEN H sold 15,842 shares
Director @ $15.78 ($250.0K)
Apr 29, 2026 earnings_calendar
BLCO Q1 2026 Earnings Scheduled — 2026-04-29
Mar 10, 2026 SEC
Bausch & Lomb CEO and Chairman Brent L. Saunders was granted 14,700 shares as a non-cash award and simultaneously purcha
CLUSTER — Impact 7/10
Mar 4, 2026 SEC
Seven Bausch & Lomb executives, including the CEO and CFO, surrendered shares for tax withholding purposes in late Febru
CLUSTER — Impact 4/10
Mar 3, 2026 SEC
Bausch & Lomb insiders showed mixed activity in the past week, with two open-market purchases totaling $156.9K and signi
CLUSTER — Impact 4/10

Price Targets

$17.88 +15.9% upside Buy
Current $15.42 Low $16.00 Median $18.00 High $21.00 12 analysts
$16.00 $21.00

Analyst Ratings

Hold50% buy · 18 analysts
3Strong Buy
6Buy
8Hold
1Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Apr 30, 2026 Evercore ISI Group MAINTAIN In-Line → In-Line
Apr 6, 2026 Evercore ISI Group MAINTAIN In-Line → In-Line
Feb 23, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Feb 19, 2026 Citigroup MAINTAIN Buy → Buy
Feb 19, 2026 Barclays MAINTAIN Equal-Weight → Equal-Weight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.16 ▲ +13.3% $0.12 — $0.24 128% YoY 13
Next Q $0.22 ▼ -1.1% $0.19 — $0.24 21% YoY 13
Current FY $0.80 ▲ +1.4% $0.75 — $0.90 58% YoY 13
Next FY $1.08 $0.93 — $1.21 34% YoY 13

Latest Reports

BULLISH CLUSTER 7/10
Bausch & Lomb CEO and Chairman Brent L. Saunders was granted 14,700 shares as a non-cash award and simultaneously purcha
Mar 10, 2026
NEUTRAL CLUSTER 4/10
Seven Bausch & Lomb executives, including the CEO and CFO, surrendered shares for tax withholding purposes in late Febru
Mar 4, 2026

Top Institutional Holders

FundValueMove
FMR LLC$24.7MDOUBLED
MORGAN STANLEY$12.2MDOUBLED
BANK OF AMERICA CORP$968.4KDOUBLED
WELLS FARGO & COMPANY/MN$101.0KADD

Recent Insider Trades

DateInsiderTypeValue
May 26, 2026Alfonso EduardoA$250.0K
May 26, 2026Bernier NathalieA$250.0K
May 26, 2026COLLIS STEVENA$250.0K
May 26, 2026KAVANAGH SARAHA$250.0K
May 26, 2026Ling KarenA$250.0K
4 institutional holders with $37.9M total value (2,221,202 shares) as of 2025-Q4. Top holders: FMR, MORGAN, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1FMR LLC1,445,333$24.7M65.1%DOUBLED +102.1%
2MORGAN STANLEY713,267$12.2M32.1%DOUBLED +668.7%
3BANK OF AMERICA CORP /DE/56,699$968.4K2.6%DOUBLED +313.3%
4WELLS FARGO & COMPANY/MN5,903$101.0K0.3%ADD +31.2%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
BANK OF AMERICA CORP /DE/DOUBLED13,72056,699+313.3%$968.4K2025-Q4
WELLS FARGO & COMPANY/MNADD4,5005,903+31.2%$101.0K2025-Q4
FMR LLCDOUBLED771,8351,560,126+102.1%$23.5M2025-Q3
MORGAN STANLEYDOUBLED97,843752,135+668.7%$11.3M2025-Q3
UBS Group AGTRIM827,768539,038-34.9%$8.1M2025-Q3
BANK OF AMERICA CORP /DE/TRIM19,41313,720-29.3%$206.8K2025-Q3
UBS Group AGTRIM1,433,470827,768-42.3%$10.8M2025-Q2
FMR LLCNEW—771,835—$10.0M2025-Q2
MORGAN STANLEYTRIM167,94197,843-41.7%$1.3M2025-Q2
WELLS FARGO & COMPANY/MNTRIM18,0694,580-74.7%$59.5K2025-Q2
RENAISSANCE TECHNOLOGIES LLCEXIT63,0000-100.0%$0.002025-Q2
UBS Group AGDOUBLED324,3831,433,470+341.9%$20.8M2025-Q1
CITADEL ADVISORS LLCTRIM1,124,652643,935-42.7%$9.3M2025-Q1
RENAISSANCE TECHNOLOGIES LLCDOUBLED20,60063,000+205.8%$913.5K2025-Q1
CHARLES SCHWAB INVESTMENT MANAGEMENT INCEXIT41,0850-100.0%$0.002025-Q1
TWO SIGMA INVESTMENTS, LPEXIT14,5000-100.0%$0.002025-Q1
CITADEL ADVISORS LLCDOUBLED517,3361,124,652+117.4%$20.3M2024-Q4
UBS Group AGDOUBLED8,185324,383+3863.1%$5.9M2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD29,75541,085+38.1%$741.7K2024-Q4
RENAISSANCE TECHNOLOGIES LLCNEW—20,600—$372.0K2024-Q4
MORGAN STANLEYADD125,125183,926+47.0%$3.5M2024-Q3
CHARLES SCHWAB INVESTMENT MANAGEMENT INCNEW—29,755—$575.6K2024-Q3
16 unique insiders with 7 transactions. Net insider value: $1.1M ($1.1M bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 26, 2026Alfonso EduardoDirectorA15,842$15.78$250.0K
May 26, 2026Bernier Nathalie D.DirectorA15,842$15.78$250.0K
May 26, 2026COLLIS STEVEN HDirectorA15,842$15.78$250.0K
May 26, 2026KAVANAGH SARAH BDirectorA15,842$15.78$250.0K
May 26, 2026Ling KarenDirectorA15,842$15.78$250.0K
May 26, 2026Paulson JohnDirectorA15,842$15.78$250.0K
May 26, 2026ROBERTSON RUSSEL CDirectorA15,842$15.78$250.0K
May 26, 2026Ross Thomas W. Sr.DirectorA15,842$15.78$250.0K
May 26, 2026VON ESCHENBACH ANDREW C.DirectorA15,842$15.78$250.0K
May 22, 2026SAUNDERS BRENT LChairman of the Board and CEOF2,886$15.92$45.9K
May 5, 2026Eldessouky SamEVP and CFOF63,938$16.00$1.0M
May 5, 2026Hashad YehiaEVP of R&D and CMOF13,664$16.00$218.6K
May 5, 2026Munsch FrederickSVP, Controller and CAOF8,673$16.00$138.8K
May 5, 2026Bonnefoy LucPresident, SurgicalF11,970$16.00$191.5K
Apr 30, 2026Alfonso EduardoDirectorA1,375$15.90$21.9K
Apr 30, 2026COLLIS STEVEN HDirectorA1,415$15.90$22.5K
Apr 30, 2026Paulson JohnDirectorA1,375$15.90$21.9K
Apr 30, 2026ROBERTSON RUSSEL CDirectorA1,611$15.90$25.6K
Apr 24, 2026Bailey A Robert DEVP & Chief Legal OfficerF15,806$15.82$250.1K
Apr 24, 2026Stewart Andrew J.President, GPICF4,216$15.82$66.7K
Mar 6, 2026Eldessouky SamEVP and CFOBUY4,000$17.13$68.5K
Mar 6, 2026Eldessouky SamEVP and CFOA4,000$0.00$0.00
Mar 6, 2026SAUNDERS BRENT LCEO and Chairman of the BoardBUY14,700$17.14$252.0K
Mar 6, 2026SAUNDERS BRENT LCEO and Chairman of the BoardA14,700$0.00$0.00
Mar 6, 2026Bailey A Robert DEVP & Chief Legal OfficerBUY14,600$17.15$250.3K
Mar 6, 2026Bailey A Robert DEVP & Chief Legal OfficerA14,600$0.00$0.00
Mar 3, 2026Ross Thomas W. Sr.DirectorBUY4,500$17.68$79.6K
Mar 2, 2026Alfonso EduardoDirectorBUY4,300$17.90$77.0K
Feb 27, 2026VON ESCHENBACH ANDREW C.DirectorBUY4,364$18.31$79.9K
Feb 27, 2026Munsch FrederickSVP, Controller and CAOF2,437$18.30$44.6K
Feb 27, 2026Stewart Andrew J.President, GPICF2,007$18.30$36.7K
Feb 27, 2026Bonnefoy LucPresident, SurgicalF4,311$18.30$78.9K
Feb 27, 2026Bailey A Robert DEVP & Chief Legal OfficerF2,461$18.30$45.0K
Feb 27, 2026SAUNDERS BRENT LCEO and Chairman of the BoardF24,649$18.30$451.1K
Feb 27, 2026Eldessouky SamEVP and CFOF15,507$18.30$283.8K
Feb 27, 2026Hashad YehiaEVP of R&D and CMOF5,075$18.30$92.9K
Feb 26, 2026Eldessouky SamEVP and CFOF7,062$18.49$130.6K
Feb 26, 2026Munsch FrederickSVP, Controller and CAOF2,042$18.49$37.8K
Feb 26, 2026Bailey A Robert DEVP & Chief Legal OfficerF3,395$18.49$62.8K
Feb 26, 2026SAUNDERS BRENT LCEO and Chairman of the BoardF22,059$18.49$407.9K
Feb 26, 2026Hashad YehiaEVP of R&D and CMOF2,169$18.49$40.1K
Feb 26, 2026Bonnefoy LucPresident, SurgicalF4,404$18.49$81.4K
Feb 26, 2026Stewart Andrew J.President, GPICF2,984$18.49$55.2K
Feb 25, 2026Munsch FrederickSVP, Controller and CAOA18,253$0.00$0.00
Feb 25, 2026Bonnefoy LucPresident, SurgicalA30,373$0.00$0.00
Feb 25, 2026Stewart Andrew J.President, GPICA32,710$0.00$0.00
Feb 25, 2026Bailey A Robert DEVP & Chief Legal OfficerA52,570$0.00$0.00
Feb 25, 2026Eldessouky SamEVP and CFOA81,775$0.00$0.00
Feb 25, 2026SAUNDERS BRENT LCEO and Chairman of the BoardA327,102$0.00$0.00
Feb 23, 2026COLLIS STEVEN HDirectorBUY15,000$17.81$267.1K
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 5 neutral. Avg impact: 4.7/10.
BULLISH CLUSTER 7/10
Bausch & Lomb CEO and Chairman Brent L. Saunders was granted 14,700 shares as a non-cash award and s
Mar 10, 2026
NEUTRAL CLUSTER 4/10
Seven Bausch & Lomb executives, including the CEO and CFO, surrendered shares for tax withholding pu
Mar 4, 2026
NEUTRAL CLUSTER 4/10
Bausch & Lomb insiders showed mixed activity in the past week, with two open-market purchases totali
Mar 3, 2026
NEUTRAL CLUSTER 3/10
Bausch & Lomb executives, including CEO Brent Saunders, participated in a stock award event on Febru
Mar 2, 2026
NEUTRAL CLUSTER 4/10
Bausch & Lomb CEO Brent Saunders was granted 327,102 shares in a non-cash award, while simultaneousl
Feb 27, 2026
NEUTRAL CLUSTER 4/10
Two Bausch & Lomb insiders purchased shares in the open market, totaling $345,910, while CEO Brent S
Feb 26, 2026
BULLISH CLUSTER 7/10
Two Bausch & Lomb insiders purchased shares in the past week, totaling $345,910, signaling confidenc
Feb 24, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Hold (50% buy). Based on 18 analysts: 3 strong buy, 6 buy, 8 hold, 1 sell, 0 strong sell.

Analyst Price Targets

$17.88 mean target +15.9% upside Buy (2.46)
$16.00 Low $21.00 High
MetricValue
Current Price$15.42
Target Low$16.00
Target Mean$17.88
Target Median$18.00
Target High$21.00
# Analysts12
RecommendationBuy (2.46)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.16 $0.12 $0.24 128.0% +13.3% 4↑ 5↓ $1.4B 7.0% 13
Next Q
2026-09-30
 $0.22 $0.19 $0.24 21.4% -1.1% 2↑ 7↓ $1.4B 6.5% 13
Current FY
2026-12-31
 $0.80 $0.75 $0.90 57.6% +1.4% 10↑ 3↓ $5.5B 7.2% 13
Next FY
2027-12-31
 $1.08 $0.93 $1.21 33.8% +0.2% 9↑ 4↓ $5.8B 5.7% 13

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.160
7d ago$0.160-0.000
30d ago$0.141+0.019
60d ago$0.155+0.004
90d ago$0.155+0.004
6 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Apr 30, 2026 Evercore ISI Group MAINTAIN In-Line In-Line
Apr 6, 2026 Evercore ISI Group MAINTAIN In-Line In-Line
Feb 23, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Feb 19, 2026 Citigroup MAINTAIN Buy Buy
Feb 19, 2026 Barclays MAINTAIN Equal-Weight Equal-Weight
Feb 19, 2026 Stifel MAINTAIN Hold Hold
Feb 19, 2026 Wells Fargo MAINTAIN Equal-Weight Equal-Weight
Feb 17, 2026 Stifel MAINTAIN Hold Hold
Jan 5, 2026 Evercore ISI Group DOWNGRADE Outperform In-Line

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263681050%
May 1, 20263691047%
Apr 1, 20263691047%
Mar 1, 20263691047%
Feb 1, 20263781053%
Jan 1, 20263781053%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 29, 2026
Clinical Trial
A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness
Phase Phase 3 — COMPLETED
May 28, 2026
FDA
Siliq
WARNING: SUICIDAL IDEATION AND BEHAVIOR Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with SILIQ. Pr
Apr 29, 2026
earnings_calendar
BLCO Q1 2026 Earnings Scheduled — 2026-04-29
Mar 16, 2026
short_interest
FTD: BLCO — 44,378 shares ($0.7M) failed to deliver
Settlement: 20260316, Price: $16.20, FTD Value: $718,923.6, BAUSCH + LOMB CORP COM (CAN)
Mar 4, 2026
FDA
Aplenzin
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS SUICIDALITY AND ANTIDEPRESSANT DRUGS Antidepressants increased the risk of suicidal thoughts and behavior in
Feb 24, 2026
Clinical Trial
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Phase Phase 3 — COMPLETED
Feb 24, 2026
Clinical Trial
Treatment With Ribavirin for Patients With Metastatic Breast Cancer
Phase Phase 2 — TERMINATED
Feb 24, 2026
Clinical Trial
Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C
Phase Phase 2 — TERMINATED
Feb 23, 2026
FDA
EFINACONAZOLE
Feb 20, 2026
Clinical Trial
Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock
Phase Phase 3 — COMPLETED
Feb 20, 2026
FDA
Diazepam
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazep